Trexo Robotics

Trexo Robotics emerged from founder Manmeet's personal experience when his nephew was born with Cerebral Palsy and told he would never walk independently. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The problem was stark: millions of children with mobility disabilities lacked practical tools to achieve independent locomotion. Children with conditions like Cerebral Palsy experienced this most acutely, facing lifelong wheelchair dependence despite having the cognitive ability to walk. The problem was measurable—therapists tracked walking ability through standardized assessments, and the gap between potential and reality was observable in therapy sessions and daily life. Existing alternatives were limited: physical therapy provided incremental gains but couldn't overcome severe motor control deficits, while wheelchairs offered mobility without addressing the psychological and developmental benefits of walking. Early validation came through therapy centers and rehabilitation hospitals that immediately recognized the device's potential. Parents reported transformative outcomes—children walking independently for the first time. Therapists noted improved muscle tone and confidence. This clinical enthusiasm from respected institutions signaled genuine demand beyond the founder's personal motivation, validating that the exoskeleton addressed a real, underserved need.

Trexo Robotics launched their MVP as a functional pediatric exoskeleton focused on children with Cerebral Palsy—deliberately omitting cosmetic refinement, wireless connectivity, and advanced AI gait optimization that competitors pursued. They shipped their first clinical units within 18 months, prioritizing weight reduction and safety certification over feature completeness. This stripped-down approach meant early users got a device that worked reliably in therapy settings, even if it looked industrial and required manual adjustments. The validation came fast: therapists and parents reported children walking independently for the first time, generating powerful word-of-mouth and case studies that attracted hospital partnerships. Rather than chasing venture capital timelines, Trexo moved methodically through clinical evidence, which built credibility with healthcare institutions. This execution strategy—shipping functional hardware quickly while accepting aesthetic limitations—proved advantageous in medical devices where efficacy trumps polish. However, the hardware-heavy manufacturing constraints later slowed their scaling compared to software-first competitors, revealing the double-edged nature of their pragmatic approach.